AbbVie to announce Q2 2025 financial results on July 31, 2025.

• AbbVie announces Q2 2025 financial results on July 31, 2025, before the market opens. • Conference call to be held at 8 a.m. Central time. • Webcast accessible on AbbVie's Investor Relations website. • Archived session available later that day. • AbbVie's mission is to discover and deliver innovative medicines and solutions. • Company focuses on immunology, oncology, neuroscience, and eye care. • Allergan Aesthetics portfolio includes products and services.

AbbVie Inc. (ABBV) has scheduled the release of its second quarter 2025 financial results for July 31, 2025, before the market opens. The company will also host a conference call and webcast to discuss these results, which are expected to provide insights into the company's performance and future outlook. The conference call is set to begin at 8 a.m. Central Time and will be accessible via AbbVie's Investor Relations website. An archived session will be available later that day for those unable to attend the live event.

AbbVie's mission is to discover and deliver innovative medicines and solutions, focusing on immunology, oncology, neuroscience, and eye care. The company's recent performance has been driven by its robust pipeline and strategic acquisitions, such as its merger with Allergan, which expanded its portfolio to include products and services for aesthetics, including facial injectables, body contouring, and skin care.

The upcoming financial results will be closely watched by investors and analysts alike. While specific earnings estimates have not been revised recently, the company's strong track record and recent positive developments in its pipeline have driven investor interest. AbbVie's earnings per share (EPS) for the current quarter are expected to be $3.24, representing a year-over-year change of +22.3% [2]. For the current fiscal year, the consensus estimate points to an EPS of $12.28, indicating a change of +21.3% from the prior year. Over the next fiscal year, the estimate is $14.06, reflecting a change of +14.4% [2].

AbbVie's Zacks Rank, a proprietary stock rating tool, currently rates the stock as a "Hold," reflecting the recent changes in earnings estimate revisions and other factors. This rating suggests a cautious approach to the stock's near-term price direction, but the company's strong fundamentals and innovative pipeline continue to position it as a leader in the biopharmaceutical industry.

Investors and financial professionals are encouraged to tune into the conference call and webcast to gain deeper insights into AbbVie's financial performance and future plans. The event will provide an opportunity to hear from senior executives, including any updates on product development, strategic initiatives, and market expansion plans.

References:
[1] https://www.gurufocus.com/news/2950303/marqeta-inc-mq-announces-upcoming-q2-2025-financial-results-conference-call-mq-stock-news
[2] https://sg.finance.yahoo.com/news/investors-heavily-search-abbvie-inc-130004575.html